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Abstract
Background: Obesity is a major risk factor of chronic-diseases, including cardiovascular-diseases
(CVD). Increasing evidence is showing the association of heat-shock protein (HSP) with type-2
diabetes and CVD; however, there is little data on the relationship between the genetic-
polymorphisms of HSP70-2 with obesity.
Aim: The present study has investigated the association between 1267HSP70-2 genetic
polymorphism and obesity in an Iranian population with 317 subjects.
Subjects and methods: Anthropometric parameters and biochemical measurements were
measured in all the samples, while genotypes were determined using PCR-RFLP. Univariate/
multivariate analyses were conducted to explore the relationship between the genetic-
polymorphisms and obesity.
Results: The data showed a significant association between 1267HSP70-2 polymorphism in
obese subjects, compared to the non-obese group. Moreover, it was observed that this
polymorphism was associated with obesity in the CAD + group, which had a high BMI
compared to non-obese controls.
Conclusion: The 1267HSP70-2 polymorphism is associated with obesity in an Iranian population,
supporting a possible potential genetic link between obesity and cardiovascular diseases.
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Introduction
Obesity is one of the major risk factors of metabolic and
chronic diseases and its prevalence is increasing worldwide
(Jou & Techakehakij, 2012; Sakowicz et al., 2013). Several
studies have identified a number of genetic variants associated
with obesity (Yu et al., 2012). In the past, genetic studies of
obesity were concentrated on the rare monogenic syndromes.
However, the associations between genetic polymorphisms
and obesity are frequently reported as heterogeneous
(Bienertova-Vasku et al., 2008; Paracchini et al., 2005).
Heat shock proteins (HSPs) belong to a multi-gene family
and their molecular weight varies from 8–150 kDa (Whitley
et al., 1999). Heat and several other stimuli such as cold, UV
radiation, alcohol, heavy metal ions, oxidation, low glucose,
infection, inflammation and hypoxia can affect heat shock
protein expression (Kiang & Tsokos, 1998). Heat shock
proteins are typically named and classified according to their
molecular size. HSP70, a 70 kDa protein, is coded by HSP70
gene (Whitley et al., 1999). Three genes that encode members
of the HSP70 class are HSP70-1 (HSPA1), HSP70-2
(HSPA1B) and HSP70- hom (HSPA1L). All three of these
genes are located in the region of MHC class III (Sargent
et al., 1989). HSP70-1 and HSP70-2 code similar proteins
with 641 amino acids (Milner & Campbell, 1990).
Some studies have shown that inflammation and high levels
of serum lipids could result in increased accumulation of lipids
in the artery wall. Accumulation of lipids induces the secretion
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of inflammatory cytokines such as tumour necrosis factor-
alpha (TNF-) from macrophages and adipocytes. TNF plays a
role in activation of the serine threonine kinase, namely JNK
(c-jun amino terminal kinase) and IKK (inhibitor of B kinase)
in insulin-responsive (Watt et al., 2006). JNK and IKK can lead
to insulin resistance by phosphorylation of the IRS-1 (Insulin
Receptor Substrate 1) (Hotamisligil, 2006) and HSP70-2
expression can inhibit the activation of the JNK and IKK.
Induction of HSP70-2 prevents insulin resistance and, thus, is
regarded as a potential target in the prevention and treatment of
obesity and type 2 diabetes (Chung et al., 2008; Hooper &
Hooper, 2009). These potential properties suggest the HSP70
gene may be a candidate in the aetiology of obesity.
There is a growing body of evidence showing that this gene
is associated with type 2 diabetes (Zouari Bouassida et al.,
2004) and coronary artery disease (Hrira et al., 2012).
Moreover, in our recent study we reported an association
between the HSP70-2 gene +1267A4G polymorphism and
cardiovascular disease in 628 Iranian patients (Mardan-Nik
et al., 2014). In the present study we have investigated further
the relationship between HSP70-2 gene polymorphisms and
obesity in an Iranian population with 317 subjects.
Materials and methods
Study population
The study population consisted of 317 patients (57.4% male
and 42.6% female, aged 35–78 years) who underwent
coronary angiography in the Ghaem Hospital Medical
Center, Mashhad, Iran (Zomorrodian et al., 2015). Of the
total group of patients, 94 were obese (BMI 30). Control
subjects (n¼ 233, 86.1% male and 13.9% female, aged 37–67
years) were healthy volunteers (93 obese and 130 non-obese).
Informed consent was taken from all the participants. The
study was approved by the Ethics Committee of the Mashhad
University of Medical Sciences (MUMS).
Biometric and biochemical measurements
Anthropometric parameters of individuals including weight,
height, BMI, waist circumference, hip circumference and
waist/hip ratio as well as systolic and diastolic blood pressures
were measured as previously described (Emamian et al.,
2015; Ghayour-Mobarhan et al., 2008; Mirhafez et al.,
2015a). Obesity was defined according to the World Health
Organisation (WHO) (Farshidi et al., 2010).
Biochemical analysis
A full fasted lipid profile was determined for each subject.
Serum lipids and fasting blood glucose (FBG) concentrations
were measured by enzymatic methods as previously described
(Ghayour-Mobarhan et al. 2008; Mirhafez et al. 2015b; Oladi
et al., 2015).
DNA isolation and SNP selection and genotyping
Genomic DNA was extracted from peripheral blood using a
commercially available DNA isolation kit (Genet bio,
Daejeon, Korea) according to the manufacturer’s protocol.
The quality of the DNA (ng/ml) samples was assessed using
agarose gel-electrophoresis and the concentration quantities
by spectrophotometry (Nano Drop 1000, Thermo Scientific,
Wilmington, NC). Genotyping for the rs1061581 polymorph-
ism was carried out using polymerase chain reaction–restric-
tion fragment length polymorphism (PCR-RFLP) technique.
Amplification of HSP70-2 gene was performed using forward
and reverse primers as follows: sense 50-
CATCGACTTCTACACGTCC-30 and antisense 50-
CGGAGTAGGTGGTGAAGATC-30. The PCR reaction was
performed in 25 ml final volume, using 100 ng of genomic
DNA, 0.2 mM dNTPs, 2 mM MgCl2, 1Taq DNA
polymerase buffer, 0.32 pmol each primer and 1 unit of Taq
DNA polymerase (Genet bio, Korea). The polymerase chain
reaction conditions were as follows: initial denaturation at
95C for 5 minutes, followed by 30 cycles denaturation at
95C for 30 seconds, annealing at 61C for 30 seconds, DNA
extension at 72C for 1 minute and the final extension at 72C
for 7 minutes. All amplification cycles were performed in
PCR system Verity 96 well thermocycler (Applied
Biosystems, CA). PCR products were digested for 16 hours
at 37C with 1 ml of PstI (Fermentas, Vilnius, Lithuania). For
separation of RFLP products, electrophoresis on 1.5% agarose
gel with ethidium bromide staining and visualising by UV
light was performed. DNA lacking polymorphic PstI site
(adenine at 1267 nt) within the HSP70-2 gene produced a
fragment of 428 bp (A allele), whereas the presence of 1267
G allele generated two fragments of 247 and 181 bp after PstI
digestion (G allele). Finally, a direct sequencing approach
(Company of Sequetech, CA) was used to confirm the
genotypes obtained by PCR-RFLP for some of the subjects in
different groups (Figure 1).
Statistical analyses
All data were analysed using the SPSS for Windows, version
22 software package (SPSS Inc, Chicago, IL). The
Kolmogorov–Smirnov test was used to test the normality of
Figure 1. PCR-RFLP of the amplified segment in 1267HSP70-2 gene.
The genotype was labelled on corresponding sequences and the sites
which were marked with black arrows were the SNP of HSP70-2 gene.
Electrophoresed on 1.5% agarose, stained with ethidium bromide. Lane
2, 100bp DNA ladder. Lane 3, 5 and 6 heterozygote for HSP70-2
genotype, Lane 4 and 7 homozygote GG for HSP70-2 genotype. Lane 1
homozygote AA for HSP70-2 genotype.
DOI: 10.3109/03014460.2015.1119309 Association of HSP70 polymorphism with obesity 543
the variables in each group. Data were expressed as median
and interquartile range (IQ3–IQ1) for data with non-normal
distribution. 2 test was used for categorical data. The
statistical difference in genotype distribution and allele
frequencies between groups was assessed by the 2 test.
Compliance of genotypes with the Hardy-Weinberg equilib-
rium in each group was also assessed by 2 test. Binary
logistic regression was used to adjust for confounders. A
2-sided p50.05 was considered significant.
Results
Demographics and clinical characteristics of
population
The demographic and metabolic characteristics of study
subjects with and without obesity are presented in Table 1.
The proportion of individuals who had coronary artery disease
and obesity was 57.4% and 42.6% in males and females,
respectively. The frequency ofobesity observed in male patients
was significantly higher compared to the female individuals
(p50.001). Total cholesterol (TC), low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol
(HDL-C), hip circumference, waist/hip ratio, hs-CRP and
FBS were significantly different between patients and control
subjects with obesity. There was also no significant difference
in the weight, waist circumference, BMI and TG: triglyceride
concentrations (p40.05). The prevalence of diabetes mellitus
and hypertension was significantly higher in the obese case
group compared to the obese control group (Table 1).
There was a statistically significant difference for
anthropometric and biochemical parameters between obese
cases and non-obese control subjects except DBP. As would
be expected, there were statistically significant differences for
hypertension and diabetes between non-obese controls and
obese cases (Table 1).
Association between 1267HSP70-2 polymorphism
and obesity
The distribution of 1267Hsp70-2 genotypes and the allelic
frequencies in study subjects are shown in Tables 2–5. There
was a deviation from the Hardy-Weinberg equilibrium in both
obese cases and controls with obesity (p50.05). To rule out
any genotyping errors, 10% of samples were genotyped. The
frequencies of AA, AG and GG genotypes were 35.4%, 53.8%
Table 1. Demographic and clinical characteristics of the subjects.







(n¼ 94) P1 P2 P3
Age, year 53 (12) 52 (14) 62 (21) — * *
Gender, n (%)Male 110 (84.6) 82 (88.2) 54 (57.4) — * *
BMI (Kg/m2) 26.3 (4.7) 32.3 (3.50) 32 (4.86) * * —
Weight (Kg) 67 (13) 80 (17.5) 80 (15) * * —
WC (cm) 94 (12) 107 (13) 103 (18) * * —
Height (cm) 161 (12) 157 (15) 81 (14) * * —
TC (mg/dl) 188 (73) 193 (86) 184 (98) — * *
TG (mg/dl) 116 (83) 140 (85) 141 (140) — * —
HDL (mg/dl) 42 (10.9) 42 (12) 38 (12.5) — * *
LDL (mg/dl) 120 (45) 113 (38) 116 (70) — * *
FBG (mg/dl) 80 (17) 84 (26) 96 (91) — * *
HC (cm) 100 (7) 110 (10) 105 (23) * * *
Waist/Hip ratio 0.94 (0.09) 0.95 (0.09) 0.99 (0.15) — * *
SBP (mmHg) 123 (28) 123 (28) 150 (30) — * *
DBP (mmHg) 80 (8) 80 (10) 80 (15) — — —
hs-CRP 2.42 (2.4) 1.99 (3.06) 2.82 (6.75) — * *
Hypertension, n (%) 211 (16.3) 31 (33.7) 61 (64.9) * * *
Diabetes, n (%) 10 (7.9) 10 (11) 40 (42.6) — * *
Values are expressed as interquartile range non-normally distributed variables. Comparisons were performed by independent samples t-test and Mann–
Whitney U-test for non-normally distributed variables.
2 of test results for categorical data.
BMI, body mass index; WC, waist circumference; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; FBG, fasting blood glucose; HC, hip circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; P1,
comparison between groups of non-obese control and obese control; P2, comparison between groups of non-obese control and obese case; P3,
comparison between groups of obese control and obese case.




(n = 93) OR (95% CI) p-value Adj. OR (95% CI) Adj.a p-value
AA, n (%) 46 (35.4) 17 (18.3) 0.304 (0.124–0.749) 0.010 0.346 (0.120–3.995) 0.049
AG, n (%) 70 (53.8) 59 (63.4) 0.694 (0.316–1.526) 0.364 0.898 (0.332–2.429) 0.832
GG, n (%) 14 (10.8) 17 (18.3) 1
A allele 162 (62.3) 93 (50.0) 0.605 (0.413–0.886) 0.01 0.589 (0.366–0.949) 0.030
G allele 98 (37.3) 93 (50.0) 1
CI, confidence interval; OR, odds ratio; TG, triglycerides.
aAdjusted for weight.
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and 10.8% in the non-obese control and 14.9, 68.1% and 17%
in obese cases, respectively. There was a significant associ-
ation in genotype distribution between the two groups
(p¼ 0.002). Compared with the GG genotype of HSP70-2
gene, subjects carrying the AA genotype showed a decreased
risk in non-obese controls (p ¼ 0.005, OR¼ 0.26, 95%
CI¼ 0.105–0.678). Similar values were obtained after adjust-
ing for individuals older than 60 years, sex, LDL-C, FBG,
HDL and waist/hip ratio. There was a significant difference in
frequency of the A allele between two groups (p¼ 0.005,
OR¼ 0.580, 95% CI¼ 0.396–0.848) (Table 4). The frequen-
cies of the AA, AG and GG genotypes were also 14.9%,
68.1% and 18.3% in the obese cases and 18.3%, 63.4% and
18.3% in the obese controls, respectively. In a dominant
analysis model of the HSP70-2 gene +1267A/G position (AA
vs AG + GG), the percentage of subjects who were either
homo- or heterozygous for the G allele (1267AG and
1267GG) was significantly higher in obese cases than non-
obese controls (85.1% vs 64.1%) (adj. p¼ 0.002, adj.
OR¼ 4.898; 95% CI¼ 1.763–13.604) (Table 5).
Association between HSP70-2 rs1061583
polymorphism and clinical-biochemical parameters
We also examined the baseline characteristics between the
genotype groups in overall groups, but there was no signifi-
cant difference except SBP and DBP in non-obese controls
(data not shown).
Discussion
The complex aetiology of obesity reflects effects of genes and
environment as well as their interactions (Bienertova-Vasku
et al., 2008). The HSP70-2 gene encodes a protein involved in
the pathophysiology of obesity and diabetes (Bouchard, 2008;
Chouchane et al. 2001; Chung et al., 2008). In this study it
was hypothesised that it might be associated with the
prevalence of obesity in Iranian population patients with
CAD.
To the best of our knowledge this is the first
study evaluating the association of 1267HSP70-2 polymorph-
ism with the prevalence of obesity in Iranian patients
with CAD. Our results showed a significant decrease of
AA genotype in the obese case group when compared with the
G allele carriers (GG and AG) (p¼ 0.005, OR¼ 0.26, 95%
CI¼ 0105–0.678), suggesting that this genotype may be
considered as a protective marker in the non-obese control
group. This observation is consistent with previous results that
indicated GG genotype in Tunisians was correlated with
obesity (Chung et al., 2008). A recent report by Zouari
Bouassida et al. (2004) demonstrated that the 1267 HSP70-
2G4A variant could convey an increased risk for obesity and
type 2 diabetes. In addition to the single locus analysis our
study indicated that there was no association between
1267HSP70-2 polymorphism in both cases and controls with
obesity (p¼ 0.77). However, allelic and genotypic frequencies
for the polymorphism of HAP70-2 + 1267A/G were




(n = 94) OR (95% CI) p-value Adj. OR (95% CI) Adj.a p-value
AA, n (%) 46 (35.4) 14 (14.9) 0.266 (0.105–0.678) 0.005 0.107 (0.021–0.546) 0.007
AG, n (%) 70 (53.8) 64 (68.1) 0.800 (0.362–1.769) 0.581 0.731 (0.244–2.192) 0.576
GG, n (%) 14 (10.8) 16 (17) 1
p = 0.002
A allele 162 (62.3) 92 (48.9) 0.580 (0.396–0.848) 0.005 0.478 (0.278–0.820) 0.007
G allele 98 (37.3) 96 (51.1) 1
p = 0.005
CI, confidence interval; OR, odds ratio.
aAdjusted for age 60; sex; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBG, fasting blood glucose;
Waist/Hip ratio.




(n = 94) p-value OR (95% CI) Adj.a p-value Adj. OR (95% CI)
AA, n (%) 46 (35.4) 14 (14.9) 1
AG-GG, n (%) 84 (64.1) 80 (85.1) 0.001 3.129 (1.598–6.128) 0.002 4.898 (1.763–13.604)
CI, confidence interval; OR, odds ratio.
aAdjusted for age 60; sex; HDL-C; high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBG, fasting blood glucose;
Waist/Hip ratio.




(n = 93) p-value OR (95% CI) Adj.a p-value Adj. OR (95% CI)
AA, n (%) 46 (35.4) 17 (18.3) 1
AG-GG, n (%) 84 (64.1) 76 (81.7) 0.006 2.448 (1.295–4.629) 0.009 2.790 (1.288–6.047)
CI, confidence interval; OR, odds ratio.
aAdjusted for weight; TG, triglycerides.
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significantly different between obese and non-obese in the
control group (p¼ 0.013; p¼ 0.006).
Pociot et al. (1993) also reported that mRNA expression in
insulin-dependent diabetes mellitus (IDDM) patients with
homozygous GG genotype was decreased compared to the
heterozygotes (AG) and hemozygotes (AA).
A major strength of this study is that it was performed in a
well-characterised cohort of individuals, with or without
obesity; however, the main limitation of this study is the
cross-sectional study design and modest sample size. In
addition, subjects with Angio had a significantly different
mean age compared to the Angio + group; however, this
variable was adjusted for in the logistic regression model.
Also, it is possible that other lifestyle characteristics, e.g. diet,
have an influence on the outcome.
In conclusion, we demonstrate the significant association
of HSP70-2 gene +1267 HSP70-2G4A polymorphisms with
obesity and show that subjects with GG genotype or those
who carried the G allele were associated with obesity,
supporting further studies on evaluating the role and expres-
sion level of this emerging marker.
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